HLA-B Inhibitors

HLA-B inhibitors function through various mechanisms to modulate the activity of HLA-B, a crucial molecule in the immune system's antigen presentation pathway. The primary mode of action for these inhibitors involves disrupting the antigen processing and presentation mechanism. This disruption can occur at different stages, including the proteasomal degradation of proteins into peptide fragments suitable for presentation by HLA-B. Inhibiting the proteasome directly impacts the availability of peptide fragments, thereby affecting the antigen presentation function of HLA-B. Additionally, some inhibitors target the transport and maturation of HLA-B molecules, including the processes of protein folding, glycosylation, and transport from the endoplasmic reticulum to the Golgi apparatus. These disruptions can affect the stability, surface expression, and overall function of HLA-B in presenting antigens to T cells.

Another significant mechanism employed by HLA-B inhibitors is the alteration of intracellular environments crucial for antigen processing. This includes modulating the acidification of endosomes and lysosomes, which are vital for the final processing of antigens before their presentation by HLA-B. By affecting the pH and enzyme activities within these organelles, the inhibitors can indirectly impact the antigen presentation capability of HLA-B. Furthermore, some inhibitors exert their effects by modulating the expression of HLA-B, such as through the inhibition of cytokines like IFN-γ that upregulate MHC class I expression. These varied mechanisms underscore the complex regulation of antigen presentation by HLA-B.